Protalix's PRX-115 shows promising Phase 1 data for chronic refractory gout, with long-term urate reduction after a single dose, but faces significant competition and safety concerns. Protalix's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback